Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy

Naimah Turner(The University of Texas MD Anderson Cancer Center), Roza Nurieva(The University of Texas MD Anderson Cancer Center), Ying C. Henderson(The University of Texas MD Anderson Cancer Center), Mark Zafereo(Texas Medical Center), Rim Ouni(The University of Texas MD Anderson Cancer Center), Sayan Alekseev(The University of Texas MD Anderson Cancer Center), Stephen Y. Lai(The University of Texas MD Anderson Cancer Center), Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), Jocelynn Colunga-Minutti(The University of Texas MD Anderson Cancer Center), Rene Rico(The University of Texas MD Anderson Cancer Center), Sarah Hamidi(The University of Texas MD Anderson Cancer Center), M. Puche(The University of Texas MD Anderson Cancer Center), Sang T. Kim(The University of Texas MD Anderson Cancer Center)
Frontiers in Immunology
May 29, 2024
10.3389/fimmu.2024.1369780
Cited by 11

Related Papers

Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
|Cancer Cell|2022|338
Dynamic Imaging Grade of Swallowing Toxicity (DIGEST): Scale development and validation
|Cancer|2016|254
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in <i> BRAF <sup>V600E</sup> </i> -Mutated Anaplastic Thyroid Carcinoma
|Thyroid|2019|229